Stock Research: Alembic Pharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Alembic Pharmaceuticals

NSEI:APLLTD INE901L01018
49
  • Value
    28
  • Growth
    69
  • Safety
    Safety
    75
  • Combined
    63
  • Sentiment
    28
  • 360° View
    360° View
    49
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Alembic Pharmaceuticals Limited is an India-based diversified pharmaceutical company. The Company is engaged in manufacturing and marketing Indian Formulations, International Generics, and Active Pharmaceutical Ingredients (APIs) across the globe. It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopedic and Gynecology. Its products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It also has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its Indian Formulations. It also specializes in treatments for urinary tract infections (UTIs).

more
Analysis

ANALYSIS: With an Obermatt 360° View of 49 (better than 49% compared with alternatives), overall professional sentiment and financial characteristics for the stock Alembic Pharmaceuticals are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Alembic Pharmaceuticals. The consolidated Value Rank has an attractive rank of 75, which means that the share price of Alembic Pharmaceuticals is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 75% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 69, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 28. Professional investors are more confident in 72% other stocks. Worryingly, the company has risky financing, with a Safety rank of 28. This means 72% of comparable companies have a safer financing structure than Alembic Pharmaceuticals. ...read more

more
Index
R/E Growth Markets
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
75 75 73 77
Growth
69 29 85 7
Safety
Safety
28 60 60 69
Sentiment
28 21 70 34
360° View
360° View
49 38 92 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
49 47 24 1
Opinions Change
20 10 42 43
Pro Holdings
n/a 28 95 72
Market Pulse
61 52 62 57
Sentiment
28 21 70 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
75 75 73 77
Growth
69 29 85 7
Safety Safety
28 60 60 69
Combined
63 66 95 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
64 66 68 72
Price vs. Earnings (P/E)
73 69 78 70
Price vs. Book (P/B)
59 62 73 72
Dividend Yield
63 67 59 65
Value
75 75 73 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
56 57 53 52
Profit Growth
70 22 83 1
Capital Growth
64 55 63 30
Stock Returns
51 19 67 9
Growth
69 29 85 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
33 56 48 54
Refinancing
49 54 52 46
Liquidity
47 70 82 87
Safety Safety
28 60 60 69

Similar Stocks

Discover high‑ranked alternatives to Alembic Pharmaceuticals and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

L&T Finance Holdings

BSE:533519
Country: India
Industry: Other Financial Services
Size: Medium
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.